<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468611</url>
  </required_header>
  <id_info>
    <org_study_id>MBP8298-SP-03</org_study_id>
    <nct_id>NCT00468611</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis</brief_title>
  <acronym>MAESTRO-03</acronym>
  <official_title>A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMS Technology Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMS Technology Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of MBP8298 compared to placebo in subjects
      with Secondary Progressive Multiple Sclerosis (SPMS)
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Negative efficacy results of the MAESTRO-01 study
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression of disease in subjects with SPMS as measured by the EDSS after 24 months of treatment</measure>
    <time_frame>24 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety of MBP8298, degree of change in the EDSS scores, effect of MBP8298 on MRI parameters, difference in relapse rates, effect on MSFC, subject's quality of life (MSQoL54) and fatigue (MFIS) after 24 months of treatment</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">510</enrollment>
  <condition>Multiple Sclerosis, Secondary Progressive</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBP8298</intervention_name>
    <description>500mg MBP8298 IV every six months for a period of two years</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male of female subjects, 18-65 years of age with a diagnosis of SPMS

          -  HLA DR2 and/or DR4 positive

          -  Absence of a relapse in the 3 months prior to baseline

          -  EDSS of 3.0 - 6.5

        Exclusion Criteria:

          -  Therapy with Beta-interferon, glatiramer acetate within 3 months or mitoxantrone,
             cyclophosphamide, methotrexate, azathioprine or any immune modulating or
             immunosuppressive drugs within 6 months of baseline

          -  Treatment with Tysabri within 2 years of baseline

          -  Females who are breast feeding, pregnant (pregnancy test at baseline) or not using a
             medically approved method of contraception regularly

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clyde E Markowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2007</study_first_submitted>
  <study_first_submitted_qc>May 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2007</study_first_posted>
  <last_update_submitted>August 12, 2009</last_update_submitted>
  <last_update_submitted_qc>August 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2009</last_update_posted>
  <keyword>Secondary Progressive Multiple Sclerosis</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

